Price T Rowe Associates Inc. MD raised its position in InMode Ltd. (NASDAQ:INMD – Free Report) by 8.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 28,310 shares of the healthcare company’s stock after purchasing an additional 2,256 shares during the period. Price T Rowe Associates Inc. MD’s holdings in InMode were worth $473,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its holdings in shares of InMode by 2.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,266,618 shares of the healthcare company’s stock valued at $37,853,000 after purchasing an additional 50,200 shares during the period. LSV Asset Management increased its holdings in shares of InMode by 0.4% in the fourth quarter. LSV Asset Management now owns 1,715,071 shares of the healthcare company’s stock valued at $28,642,000 after purchasing an additional 6,300 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of InMode by 4.4% in the fourth quarter. JPMorgan Chase & Co. now owns 1,084,241 shares of the healthcare company’s stock valued at $18,107,000 after purchasing an additional 45,638 shares during the period. River Road Asset Management LLC acquired a new position in shares of InMode in the fourth quarter valued at approximately $8,572,000. Finally, Yelin Lapidot Holdings Management Ltd. increased its holdings in shares of InMode by 0.6% in the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 308,852 shares of the healthcare company’s stock valued at $5,158,000 after purchasing an additional 1,950 shares during the period. Hedge funds and other institutional investors own 68.04% of the company’s stock.
Analyst Ratings Changes
A number of research analysts recently weighed in on INMD shares. Baird R W lowered InMode from a “strong-buy” rating to a “hold” rating in a report on Monday, April 28th. UBS Group dropped their price objective on InMode from $19.00 to $16.25 and set a “neutral” rating on the stock in a report on Tuesday, April 29th. Robert W. Baird lowered InMode from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $22.00 to $16.00 in a report on Monday, April 28th. Jefferies Financial Group dropped their price objective on InMode from $16.00 to $15.00 and set a “hold” rating on the stock in a report on Monday, April 14th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a report on Monday, April 28th. Seven analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, InMode currently has an average rating of “Hold” and a consensus price target of $18.54.
InMode Stock Down 0.5%
Shares of NASDAQ INMD opened at $14.92 on Wednesday. InMode Ltd. has a fifty-two week low of $13.68 and a fifty-two week high of $19.85. The business has a 50 day moving average price of $16.26 and a two-hundred day moving average price of $17.40. The firm has a market cap of $1.04 billion, a PE ratio of 6.35 and a beta of 2.02.
InMode (NASDAQ:INMD – Get Free Report) last announced its quarterly earnings results on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.14). The company had revenue of $77.87 million during the quarter, compared to the consensus estimate of $82.21 million. InMode had a return on equity of 18.25% and a net margin of 45.91%. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period last year, the business posted $0.32 EPS. On average, analysts anticipate that InMode Ltd. will post 1.75 earnings per share for the current year.
InMode Company Profile
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Further Reading
- Five stocks we like better than InMode
- Do ETFs Pay Dividends? What You Need to Know
- NVIDIA Stock Surges on Bullish News: How High Could It Climb?
- What is a Special Dividend?
- Why Boeing May Be Ready to Take Off After Latest Developments
- Asset Allocation Strategies in Volatile Markets
- eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner?
Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InMode Ltd. (NASDAQ:INMD – Free Report).
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.